Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05497349

Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis

Sponsor: Istituto Ortopedico Rizzoli

View on ClinicalTrials.gov

Summary

The aim of the study is to compare the efficacy up to 12 months of two different types of PRP (PRP with leukocytes vs PRP depleted of leukocytes) in the echo-guided infiltrative treatment of hip OA by including 230 patients in the study and evaluating them through subjective (using the WOMAC score as the primary outcome) and objective clinical scores.

Official title: Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis. Double-blind Controlled Randomized Clinical Trial

Key Details

Gender

All

Age Range

35 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

230

Start Date

2022-10-05

Completion Date

2026-10

Last Updated

2025-09-24

Healthy Volunteers

Conditions

Hip Osteoarthritis

Interventions

OTHER

Leukocyte Rich- PRP injection

Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint

OTHER

Leukocyte Poor- PRP injection

Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint

Inclusion Criteria: * Signs and symptoms of hip OA (pain intensity of at least 4 points and not more than 8 of VAS pain - 0-10 scale in the previous week); * Radiographic signs of hip OA (Grade 1-2 according to Tonnis classification) or MRI signs (chondropathy or minimal labrum degeneration without acute lesions) even if Grade 0. * Unilateral involvement; Hemoglobin \> 11 g/dl; * Platelet count \> 150,000 plt/mm3 (Recently performed CBC examination); * Negative serological tests for HBsAg, HCV Ab, HIV-1-2 Ab * No clinically significant electrocardiographic changes (Recently performed ECG). * Ability and consent of patients to actively participate in clinical follow-up;- Signature of informed consent. Exclusion Criteria: * Patients unable to express consent; * Patients undergoing infiltration of other substance in the previous 6 months; * Patients undergoing lower limb surgery to be treated in the previous 12 months; * Patients with malignant neoplasms; * Patients with rheumatic diseases;- Patients with uncontrolled diabetes;-Patients with hematological diseases (coagulopathies); * Patients on anticoagulant-antiaggregant therapy that cannot be discontinued for at least 3 days prior to blood collection; * Patients with uncontrolled thyroid metabolic disorders; * Patients abusing alcoholic beverages, drugs or medications; * Body Mass Index \> 30; * Patients who have taken NSAIDs in the 3 days prior to blood draw; * Patients with cardiovascular disease for whom 300 ml blood draw would be contraindicated; * Patients with recently performed CBC examination with Hb\< 11 g/dl and Platelet values \< 150,000 plt/mm3. * Positive serological tests for HBsAg, HCV Ab, HIV-1-2 Ab * Pregnant and/or fertile women. * Pain intensity less than 4 points or greater than 8 in accordance with the VAS scale. * Patients with other hip pathologies: acetabular protrusion, concentric migration of the femoral head, presence of excessive deformity resulting from acetabular or femoral head dysplasia, collapse deformity, and deformed femoral head sequelae of Perthes disease or osteonecrosis of the femoral head. * Previous extensive surgery of the reference joint (osteotomy around the hip, open or arthroscopic osteochondroplasty for femoro-acetabular conflict).

Locations (1)

Istituto Ortopedico Rizzoli

Bologna, Italy